Candesartan Cilexetil/Hydrochlorothiazide

Tier C — Watch / trade

Takeda Pharmaceutical Company Limited

Originator

2000

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：Thiazide-sensitive sodium-chloride cotransporter, AT1

Brand：Ratacand plus, Atacand HCT, Atacand plus, Blopress Plus, Ecard

Indications (approved)：Hypertension

Regional status

Approved

2000-09-05

China

Approved

2011-01-28

Japan

Approved

2009-01-21

Factories producing this API10

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

10 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Candesartan Cilexetil/Hydrochlorothiazide?

Approved indications include: Hypertension.

When does the Candesartan Cilexetil/Hydrochlorothiazide patent expire?

No public expiry year is available for Candesartan Cilexetil/Hydrochlorothiazide yet; this page updates once verified.

How do I get a quote for Candesartan Cilexetil/Hydrochlorothiazide intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27